

# Kidney Cancer (Renal Cell Carcinoma) Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage:  0  I  II  III  IV  Recurrent

Line of Treatment:  Neoadjuvant/Pre-Op  Adjuvant/Post-Op  First Line  Second Line  Third Line  Third Line +

ECOG Performance Status:  0  1  2  3  4

Biomarker:

Prior therapy: \_\_\_\_\_

Renal cancer risk:  Poor risk  Intermediate risk  Good risk

## Metastatic disease | First line of therapy (1<sup>st</sup> line)

High dose intravenous (IV) interleukin-2 (IL2, Proleukin) (clear cell only)

Pazopanib (Votrient)

## Metastatic disease | First line of therapy (1<sup>st</sup> line) | Poor prognosis\* or non-clear cell histology

Temsirolimus (Torisel)

## Metastatic disease | Second or subsequent lines of therapy (2<sup>nd</sup> line+) | Clear cell carcinoma

Nivolumab (Opdivo)

\*Poor prognosis patients have 3 or more of the following predictors of short survival:

- LDH greater than 1.5 x normal
- Hemoglobin less than normal (anemia)
- Corrected serum calcium (Ca) greater than 10 ng/dL
- Less than 1 year from diagnosis to the start of systemic therapy
- Karnofsky performance status  $\leq$  70 (Unable to carry on normal activity or do active work, but able to perform self-care)
- 2 or more sites of organ metastases

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

